This morning Robyn Karnauskas, the biotechnology analyst at Deutsche Bank argues that strong sales performance by Lucentis in Europe (where the drug is sold by Novartis, which reported earnings this morning) bode well for Eylea in an eye disease call diabetic macular edema.

FORBES: Could Novartis' Earnings Be Good For Regeneron?